Cyclosporine News and Research

RSS
Cyclosporine is a drug used to help reduce the risk of rejection of organ and bone marrow transplants by the body. It is also used in clinical trials to make cancer cells more sensitive to anticancer drugs.
Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

Inspire third quarter net loss decreases to $7.6 million

Inspire third quarter net loss decreases to $7.6 million

Allergan third quarter diluted loss per share increases to $2.21

Allergan third quarter diluted loss per share increases to $2.21

Immune system may play a role in cancer therapies: Study

Immune system may play a role in cancer therapies: Study

Inspire presents data on denufosol therapy for cystic fibrosis at NACFC conference

Inspire presents data on denufosol therapy for cystic fibrosis at NACFC conference

BARACLUDE sNDA receives FDA approval for treatment of CHB patients with decompensated liver disease

BARACLUDE sNDA receives FDA approval for treatment of CHB patients with decompensated liver disease

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

Researchers develop genetic screening method to identify drug-resistant HCV strains

Researchers develop genetic screening method to identify drug-resistant HCV strains

Inspire Pharmaceuticals to present denufosol tetrasodium therapy data at ERS Annual Congress

Inspire Pharmaceuticals to present denufosol tetrasodium therapy data at ERS Annual Congress

International study to improve treatments for Duchenne muscular dystrophy

International study to improve treatments for Duchenne muscular dystrophy

FDA approves Novartis' Tekamlo for treatment of high blood pressure

FDA approves Novartis' Tekamlo for treatment of high blood pressure

Inspire Pharmaceuticals, Allergan sign amended agreement for ophthalmic formulations

Inspire Pharmaceuticals, Allergan sign amended agreement for ophthalmic formulations

3Sbio, Isotechnika Pharma sign development and commercialization agreement for voclosporin inhibitor

3Sbio, Isotechnika Pharma sign development and commercialization agreement for voclosporin inhibitor

3SBio and Isotechnika enter strategic agreement for voclosporin in China

3SBio and Isotechnika enter strategic agreement for voclosporin in China

Inspire second-quarter total revenue increases 18% to $27.3 million

Inspire second-quarter total revenue increases 18% to $27.3 million

Endo Pharmaceuticals total revenues for second-quarter 2010 increase 6% to $396.5 million

Endo Pharmaceuticals total revenues for second-quarter 2010 increase 6% to $396.5 million

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

Welchol plus metformin combination therapy reduces A1C, LDL-C levels in type 2 diabetes patients

Welchol plus metformin combination therapy reduces A1C, LDL-C levels in type 2 diabetes patients

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone